Sharda Cropchem Limited (NSE:SHARDACROP)
India flag India · Delayed Price · Currency is INR
1,126.00
-6.20 (-0.55%)
May 8, 2026, 3:29 PM IST
← View all transcripts

Q1 22/23

Jul 25, 2022

Operator

Please note that this conference is being recorded. I now hand the conference over to Mr. Manish Mahawar from Antique Stock Broking Limited. Thank you, and over to you, sir.

Manish Mahawar
SVP of Institutional Equities, Antique Stock Broking Ltd

Yeah, thank you, Yashvi. On behalf of Antique Stock Broking, I would like to welcome all the participants on the call of Sharda Cropchem. From the management, we have Mr. R.V. Bubna, Chairman and Managing Director, Mr. Ashok Vashisht, CFO, and Mr. Dinesh Nahar, GM Finance on the call. Without further ado, I would like to hand over the call to Mr. Bubna for opening remarks, post which we will open the floor for Q&A. Thank you. Over to you, Mr. Bubna.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Thank you, Manish. Good evening, and very warm welcome to everyone present on the call. I hope all are keeping safe and healthy during these times. Along with me, I have Mr. Ashok Vashisht, Chief Financial Officer, and Mr. Dinesh Nahar, General Manager and SGA, our investment relations advisors. Hope you all have received our investor deck by now. For those who have not, you can view them on the stock exchanges and company website. We are a fast-growing global agrochemical company with a premier position in generic crop protection chemical industry. Our vast and growing library of dossiers and IPRs provide us solid foundation for the growth in the global marketplace, especially in advanced markets such as Europe, North America, and Latin America. It equips us with the ability to operate in a diversified range of formula and generic active ingredients space globally.

The company continues to identify opportunities in the generic molecules and corresponding formulations and generic active ingredients, preparing dossiers and seeking registrations in the relevant jurisdictions. Sharda Cropchem's total product registrations stood at 2,719 as on 30th June, 2022. Additionally, 1,153 applications for the product registrations globally are at different stages of approval. The CapEx of Q1 FY 2023 stood at INR 102 crore. We are placing special focus on expanding its biocide registrations while scaling up its marketing and distribution capabilities across geographies. We maintain relationships with multiple manufacturers in the agrochemical industry, mainly in China and India. Sourcing from multiple manufacturers help us in getting quality products at optimal price, thereby de-risking its sourcing capabilities. Over the years, we have built a strong brand franchise within our global markets.

We are benefiting through the economies of scale in our portfolio and leveraging value of our supply chain to deliver value to our customers across geographies. For Q1 FY 2023, revenues grew by 32% at INR 825 crores. I'm referring to the same period last year, I mean, not on the previous quarter. Revenue growth was led by better price realizations and product mix. Gross margins were impacted by weakening of euro versus dollar, leading to an increased input cost and impact on higher freight costs. Major currencies have depreciated against U.S. dollar in the last quarter due to ongoing war between Russia and Ukraine.

Nearly 50% of our Q1 FY 2023 sales from agrochemical business has been to the European region, whereas majority of the company's raw material is imported from China and payments are made in U.S. dollar. This has impacted the company's gross margin and overall profitability as the euro had considerably depreciated against dollar during the quarter. PAT was impacted by higher depreciation and Forex losses of INR 43.2 crores in FY 2023 versus a gain of INR 11.5 crores in Q1 FY 2022, impacting to the tune of INR 54.7 crores. We are evaluating various measures to mitigate the adverse impact of Forex going forward. We have accelerated focus on revenue-generating investments and are continuously looking to improve the operational efficiencies, which will help us improve the margins.

With this brief overview, I would now like to hand over the call to our CFO, Mr. Ashok Vashisht, for discussing our financial performance. Thank you very much.

Ashok Vashisht
CFO, Sharda Cropchem

Thank you, sir. Good evening, everyone. Coming to the Q1 FY 2023 performance, revenue stood at INR 85 crore against INR 623 crore in quarter one last year, registering a thirty-two percent year-on-year. Our revenue growth was, you know, led by better price realization and, you know, product mix. We had a favorable price and product mix impact of nearly 38%, coupled with exchange loss of 3.3% during the quarter. During the quarter, there was a marginal degrowth in volume to the tune of 2.5%, mainly in LATAM and NAFTA. Our gross margins stood at 25.4%, marginally lower comparatively, essentially due to weakening of euro versus dollar and also due to slight increase in the freight cost.

EBITDA has grown by 4% in absolute terms to INR 111 crore. However, percentage EBITDA margins is lower due to lower gross margins and slight increase in the freight cost. PAT stood at INR 23 crore in Q1 FY 2023 versus INR 38 crore in quarter one FY 2023 last year. Our PAT has, as you might have seen in our presentation, PAT was mainly impacted by forex losses to the tune of INR 43.2 crore in quarter one FY 2023, driven by weakening of the euro versus gain of INR 11.5 crore in FY 2022, impacting to the tune of rupees INR 54.7 crore. The euro has weakened against the U.S. dollar by nearly 7% in the, you know, last three months from April to June 2022.

Coming to the split agrochemicals, you know, business grew by 15% year-on-year to INR 615 crores, whereas there is a growth of 137% in a non-agro business. We achieved the turnover INR 210 crores in non-agro business. In the agrochemical space, Europe grew by impressive 24%. NAFTA region grew by 10% in value sales. Latin America grew by 2% in terms of value sales. Whereas sales in the rest of the world grew by 18%. Europe continue to, you know, contribute at 51%, NAFTA region 31%, but Latin America 13%, and the rest of the world 5% of the agrochemical business for Q1 FY 2023.

In the non-agrochemical space, Europe grew by 143%, the NAFTA region grew by 196%, LATAM grew by 165%, and the rest of the world grew by 13%. In non-agro space, Europe contributes nearly 28%, NAFTA 55%, LATAM 6%, and the rest of the world 11%. With this, we now open the, you know, floor for questions. Thank you very much.

Operator

Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. We have our first question from the line of Chirag Setalvad from HDFC Mutual Fund. Please go ahead.

Chirag Setalvad
Senior Fund Manager, HDFC Mutual Fund

Good evening, sir.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Good evening.

Chirag Setalvad
Senior Fund Manager, HDFC Mutual Fund

You pointed out the pressures on profitability. If you could help us understand what is the company doing to mitigate that, and where do you see sustainable profitability, both gross margin and EBITDA margin, in the near term?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

You see, this slide in euro versus dollar was not predictable in advance for us to plan a strategy. Even today, the experts say that the euro is going to go strengthen up. We are little bit handicapped in making a solid strategy towards this end. We are thinking of buying our supplies in euro from China. We are also afraid that if we buy them in euro and if the euro goes up, then we will lose the opportunity to make up for the loss that we have already incurred. We are keeping a close watch on the situation and we will slowly act.

Chirag Setalvad
Senior Fund Manager, HDFC Mutual Fund

Where do you see the near-term profitability settling at a gross margin level? Because you would have taken some price increases as well to take care of the freight cost changes. Where do you see sort of in the sort of second half of this year profitability at a gross margin and an operating margin level?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

We feel we should be getting nearer to last year's gross margins in the course of time.

Chirag Setalvad
Senior Fund Manager, HDFC Mutual Fund

Sure. That's it. That is it from my side. Thank you.

Operator

Thank you, Mr. Setalvad. We have our next question from the line of Harsh Beria, Professional Investor. Please go ahead.

Harsh Beria
Professional Investor, Private Investor

Hi. Thanks for the opportunity. My question is about the high growth in the non-agro business. What is contributing to such high growth in the non-agro business? It cannot be that the end market is growing at these rates. Can you expand a bit about it?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

No. End market is not growing at the same rate, but we are able to get a better share in the existing market, mainly because of our strategies and providing service to the customers by delivering our products on time and with good quality.

Harsh Beria
Professional Investor, Private Investor

Very okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Agro will also grow, so the proportion may not be so much different than what it is in this quarter. Both the businesses are expected to grow.

Harsh Beria
Professional Investor, Private Investor

Can you elaborate on your marketing strategies? Was there a change that happened recently that has contributed to such high growth?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Mainly concentrating on our sourcing to get the goods manufactured because they are tailor-made products to get them manufactured in right time and probably Chinese suppliers were also a little bit free to help us in this matter. Also pushing on the shipments in spite of increased costs, are not waiting for the cost to come down or not negotiating much on this. Main thing was to deliver the goods on time to the customers.

Harsh Beria
Professional Investor, Private Investor

Okay. I think last quarter you had highlighted that the margins have been hit in this division. Can you tell us, like, what were the margins this quarter in the non-agro business?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

One minute. See, margins, region-wise, I'll tell you. The margins were about 22% in this quarter compared to the same about 14% in the last year.

Harsh Beria
Professional Investor, Private Investor

Okay. That's it from my side. Thank you for taking my question.

Operator

Thank you.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Thank you.

Operator

We have our next question from the line of Ankush Agrawal from Surge Capital. Please go ahead.

Ankush Agrawal
Founder, Surge Capital

Sir. Hi, sir. Thanks for taking my question. Firstly, I wanted to understand a little bit on the business front. Would it be possible for you to explain, you know, some of the reasons why, you know, the generic penetration in the agrochemical is very small compared to, you know, something like a pharma industry?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Your voice is not very much audible. It's getting cut in between. Can you please-

Ankush Agrawal
Founder, Surge Capital

Is it better now?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Please repeat.

Ankush Agrawal
Founder, Surge Capital

Is it better now?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Can you please repeat one second, and speak with little slower speed?

Ankush Agrawal
Founder, Surge Capital

Sir, what I wanted to understand was that, you know, what are the reasons because of which the penetration of generics is very low in the agrochemical space compared to something like a pharma industry when, you know, the generics command a very high market share compared to the, you know, innovators.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, your question is not very clear. You are comparing the share of generics in the agrochemical business compared to the share of generics in the pharma? Are you trying-

Ankush Agrawal
Founder, Surge Capital

Yes.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

I mean, is that?

Ankush Agrawal
Founder, Surge Capital

Yes. Yes. Yes.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, I'm not able to comment on what is happening in the pharma.

Ankush Agrawal
Founder, Surge Capital

No, I'm trying to understand, you know, what are the reasons why in the agrochemical generics contribution, market share is very small. You know, what are the reasons why, you know, generics has not been able to penetrate more in the agrochemical?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes. Yes. I'll tell you. I have been answering this question repeatedly in the various calls, and I'll repeat it once again. The cost of registration in agrochemicals is very high.

Ankush Agrawal
Founder, Surge Capital

Yes.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

The time period is also much longer.

Ankush Agrawal
Founder, Surge Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Both these factors, I mean, it may take two years, four years, even seven years. These are the two factors which prevent normal investors or normal people in this line to plunge themselves into the registrations of agrochemical business.

Ankush Agrawal
Founder, Surge Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

In pharma, the cost of registration is much lower.

Ankush Agrawal
Founder, Surge Capital

What I'm trying to understand over here is the point that you're making is right. But since Sharda is a company, we have the registration, but how, why are we not able to penetrate, you know, because since we have the registration right?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

We are not able to penetrate.

Ankush Agrawal
Founder, Surge Capital

Yeah, that much. You know, the argument that you're making, you know, there are not a lot of players, is fine. That obviously there are not a lot of players. Even with one, two players that are there in the generic, why are they not able to penetrate?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, the multinational companies have a name and reputation. People have much better trust on them than a generic company. It takes a lot of time for the generic company to establish itself and win the confidence of the customers that we are competent to provide them the quality and deliveries on time.

Ankush Agrawal
Founder, Surge Capital

Yes.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

It's a very slow process.

Ankush Agrawal
Founder, Surge Capital

All right. Got it. Sir, secondly, you know.

Operator

Mr. Agrawal.

Ankush Agrawal
Founder, Surge Capital

Yeah.

Operator

I'm sorry. Can you please come back in the queue?

Ankush Agrawal
Founder, Surge Capital

That was just one question I believe, but either way, okay, I'll get back in the queue.

Operator

Thank you, sir. We have our next question from the line of Rohan Gupta from Edelweiss. Please go ahead. Participants are requested to restrict their questions to two at a time.

Rohan Gupta
Associate Director, Edelweiss

Good evening, R.V. Bubna.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, good evening, sir.

Rohan Gupta
Associate Director, Edelweiss

First, good evening, sir. Sir, first question is on our gross margin. Though in the first question you tried to answer that we are still not sure that how we will be able to make sure that our margins are not impacted given the currency volatility. You mentioned that you also have an option to buy in euro from China and then sell it in euro as well. Given the volatile scenario in which we are, don't you think that it will be prudent for us to act fast and make sure that the business margins are not being impacted with the current volatility and take the decision accordingly rather than keeping it open and depending on how the currency's movement will be happening going forward, rather than focusing more on the business margin, sir?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, we are not very sure. When the euro-dollar ratio went up to 1.05 to one, everybody was advising that is the bottom. From here, all the experts from the foreign exchange markets. If we had known that it will come down to 1.0 to one, we would have immediately acted.

Rohan Gupta
Associate Director, Edelweiss

Sir, we have seen that.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

This has been going on, Rohan , all this time, week after week and month after month, you know. The scene was never clear to anybody. We do not want to speculate. We would like to be very careful that we do not lose the opportunity when the euro starts taking the about-turn.

Rohan Gupta
Associate Director, Edelweiss

sir, absolutely right. That's what you just mentioned, that we are not in the business of currency trading, sir. I mean, we could have option of hedging it with the currency hedge or rather than waiting and watching when the rupee dollar or, I mean euro- dollar will come back to this, the level what you are looking for. I mean, wouldn't it be prudent to have the sufficient hedge so that we can protect our margins in the current scenario? That's what my limited question was, sir. Nobody is expert of making the prediction on the currency. I understand.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes.

Rohan Gupta
Associate Director, Edelweiss

We don't know how and when it will come back, but at least we can take a sufficient hedge to protect ourselves from the currency volatility.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

See, Mr. Rohan, the only hedge we do right now is to book forward contracts, where we also get some premium on this and protect it. Nobody was sure that it will go to the level of 1:1 . Every time we were advised that now it'll start moving up, this is right time. There's going to be this committee meeting in Europe or that committee meeting and all that, you know. Even today, nobody is able to say that it will go below 1: 1. If it starts doing that, then that is where we prove that we lost the opportunity. We are keeping a watch, sir, and very careful what we are doing, and we will take care as much as we can. We do not want to speculate.

Rohan Gupta
Associate Director, Edelweiss

Right, sir. Sir, second question on this. Definitely our business model is more dependent on China and which is based in a dollarized revenue, I mean dollarized purchases, while we will sell in Europe. I think the problem which we have faced, not many other innovators will be facing the same issue because they may be more or less dependent on China or more dependent on their local markets. Because we are completely dependent on China for the imports of raw material and selling in a European market, other innovators may not be facing the same issue. And that's what you see that it is difficult for us to increase the pricing or to pass it on to the end customers in European markets.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

See, Mr. Rohan, I want to give you a general information. China is exporting huge quantity of agrochemicals, and all the exports is in U.S. dollars.

Rohan Gupta
Associate Director, Edelweiss

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

The buying, purchasing in Europe is mainly in euros or European currencies. All those operations are impacted adversely in this situation. In fact, I had mentioned last time that now I'm told that even the European manufacturers, multinational manufacturers, are shifting their manufacturing into China because of various issues of fuel and energy in Europe. All these businesses will be adversely impacted with this euro or U.S. dollar uncomfortable exchange rate. Only those people who are exporting from other regions, like in India, where the dollar has become stronger than the Indian rupee, these people are getting benefited. The rest of the world, most of the people are sourcing in U.S. dollars and selling in their currencies in the countries where they are selling.

Rohan Gupta
Associate Director, Edelweiss

Sir, with this, other European players are also facing the same issue what we have. Are we seeing that we also have pricing power and we are able to pass it on to the end customers? I mean, when you are selling the materials now in the market, do you see that you are able to pass it on completely to the end customers even including the currency depreciation?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

We are making efforts and in fairly good proportion, we are also successful, but it will take time. Because we cannot, we don't want to lose our market share for some percentage of margins. We also want to keep rapport with our customers and keep on increasing the share. Both the things are contradictory, but we are trying to control both of them.

Rohan Gupta
Associate Director, Edelweiss

Fair enough, sir. Last question from my side. I'll come back in queue. Sir, on the.

Operator

Thank you.

Rohan Gupta
Associate Director, Edelweiss

On the current quarter, the.

Operator

I request you to come back in the queue, please.

Rohan Gupta
Associate Director, Edelweiss

In the queue, Rohan. In the queue. Okay, sir. Thanks.

Operator

Thank you.

Rohan Gupta
Associate Director, Edelweiss

I'll come back in queue.

Operator

Participants are requested to restrict their questions to two at a time. We have our next question from Sonal from Prescient Capital. Please go ahead.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sonal from?

Operator

Prescient.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Hi, sir. This is Sonal. This is Sonal from Prescient Capital. I hope I'm audible.

Operator

Yes, you are. Please go ahead.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Yes. First question is more around the numbers. For the agrochemical business, we've seen 15% revenue growth. Can you split this into value and volume? That's just the first bookkeeping question.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes, please.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Is my question clear?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Your question is clear.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

I need to get hold of some documents.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Sure. Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Now, you mean, you want to know the volumes?

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

The volume and the value split of the 15% top line growth for the agrochemical business.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Oh, 15%. Sir, volume-wise, volume growth has been - 2.5%. Forex impact is - 3.3%, and the product and price mix have been positive by almost 38%.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

It is thirty-two point four percent.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

That is for the whole company, if I'm not wrong, right?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes. Yes, please.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay. I was specifically asking for the agrochemical business. If you could, if you have those numbers.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

I think I'll check.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Otherwise. Yeah.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes, sir.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

If you have it, that would be helpful, sir.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, agrochemicals have grew by 15%.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Now you want segment-wise. Do you have that detail with you?

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

How much price rise have you taken roughly in agri chem?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

In Europe.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

In Europe, agrochemicals have grown by 24%. NAFTA region, 10%. LATAM is degrowth of 2%.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Rest of the world is 18%. Overall, 15%.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Got it, sir. Sir, how much price rise would we have taken in agri chem roughly? In this quarter.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

This is price and product mix. Sir, I have total basis. That chart is not yet ready with me.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Sure, sir. I'll check on that later. I have a second question, sir, also, which I wanted to get an understanding of. Wanted to understand the demand scenario in Europe and NAFTA as we speak right now. You seeing any kind of softening or inventory being built up too much because of which the demand is tapering? I just wanted to understand a subjective commentary from your side on this basically. If you have numbers.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes, sure.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

on the market. Yeah. Yeah.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, demands in the European region are fairly good and there's no cause of worry at all. In NAFTA region, there has been a pressure on the demand, mainly because of the weather, and weather has been very arbitrary in NAFTA region. Some were very heavy snow and storms and some were totally dry.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

That has put a pretty adverse pressure on the demand in NAFTA region.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay.

Operator

I need you to come back in the queue, please.

Sonal Minhas
Co-Founder and Managing Partner, Prescient Capital

Okay. I was just asking on this one only, ma'am, but I can come back in the queue. It's okay. Yeah. That's it.

Operator

Thank you. We have our next question from the line of Tarang Agrawal from Old Bridge Capital. Please go ahead.

Tarang Agrawal
Investment Analyst, Old Bridge Capital

Good evening, sir. Just wanted to get agrochemical volumes, regional agrochemical volumes and regional gross margins?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes, please. Regional agrochemicals volume. In Europe, it is three, almost 4 million units versus 3.5 million last year. How much is it?

Ashok Vashisht
CFO, Sharda Cropchem

INR 3 million.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

3 million, no? 4 million and 3.5 million.

Ashok Vashisht
CFO, Sharda Cropchem

Approximately.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Approximately. Four million versus INR 3.5 million in the same period last year. NAFTA region, it is INR 2 million versus INR 2.4 million. Degrowth of about 17%. LATAM, Latin America, it is INR 1.1 million versus INR 1.5 million, about minus 28%. Rest of the world, INR 300 thousand versus INR 340 thousand.

Tarang Agrawal
Investment Analyst, Old Bridge Capital

Gross margins?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Gross margins. Gross margins in agro business. In Europe it is 31% versus 42%. NAFTA, 24% versus 25%. Latin America, 17% versus 17%, almost flat. Rest of the world, 23% versus 31%.

Tarang Agrawal
Investment Analyst, Old Bridge Capital

Okay. Thank you.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Overall, 26.3% versus 31.9%.

Operator

Mr. Agrawal?

Tarang Agrawal
Investment Analyst, Old Bridge Capital

Yes, that's what I mean. Thank you.

Operator

Okay, thank you. We move on to the next question from the line of Alisha Mahawala from Envision Capital. Please go ahead.

Alisha Mahawala
Analyst, Envision Capital

Hi, sir. Good evening. Thank you for taking my question. Firstly, I'd like to understand with respect to gross margins, the sharp decline we've seen, is that completely and only because of, the Forex? Can you clarify?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Madam, you have to raise your voice.

Operator

Mahawala, yeah.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

And-

Operator

Please increase your voice. The volume.

Alisha Mahawala
Analyst, Envision Capital

Am I audible? Sir, am I audible now?

Operator

A little better, but it can be more better.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Very much better.

Alisha Mahawala
Analyst, Envision Capital

Am I audible now?

Operator

Can you speak in a sentence, please?

Alisha Mahawala
Analyst, Envision Capital

Sure. I hope I'm audible now.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes.

Alisha Mahawala
Analyst, Envision Capital

Sir, I wanted to understand with respect to gross margins the sharp decline that we have seen. Is this only because of the Forex impact?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Mainly, yes.

Alisha Mahawala
Analyst, Envision Capital

Sure. Considering the kind of weak volume growth that we've seen in Q1, do we want to continue with our guidance of 1500% top line growth for the full year?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes. Hopefully, yes.

Alisha Mahawala
Analyst, Envision Capital

Sure. Just lastly, the kind of CapEx spend which is largely R&D or registration related, INR 100 crores, could we expect that to continue for the remaining quarters, or are we expecting any spike in that?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

We expect to be continuing the same range, maybe a slight increase.

Alisha Mahawala
Analyst, Envision Capital

Sure. Thank you.

Operator

Thank you. We have our next question from the line of Bhavya Gandhi from Dalal & Broacha. Please go ahead.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Yeah. Thank you so much for taking my question. Sir, did we have any one-off effect in last quarter maybe because our competitors were not functioning or, we had, you know, sort of good relations with China and we got one-off benefit?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

It is not clear. Again, I'm not able to grasp it.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Uh-

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Speak a little slowly and louder.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Okay. Can you hear me now?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

I can hear you, but you have to speak little slow. I mean, by speed.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Okay. Last quarter, did we have any one-off benefit because our competitors were not functional and we had good relations in China and we were able to supply, you know, to the customers?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

See, the first part was not true. The second part is true. We have good relations with the suppliers in China, and we were able to get good support from them.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Okay. There was no one-off impact in last quarter, right?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

No, not at all.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Sir, can you just provide revenue, EBITDA and PAT guidance for FY 2023 and 2024?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

2023 and 2024?

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Yeah. Hello?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, I can provide for 2023.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

We hope to maintain our growth about 15%-20% and EBITDA at the range of 18%-20%.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Okay. Fair enough. Sir, you mentioned about European companies shifting their manufacturing to China. Will that lead to some sort of demand softening?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Demand softening?

For our company.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Because then procurement from China would become easier.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Will become easier?

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Directly procuring from China would become easier and sort of, will it be some revenue loss to us?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

No, sir. No such thing.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Okay. Any specific reason for shifting to-

Operator

I ask you to come back in the queue.

Bhavya Gandhi
Equity Research Analyst, Dalal & Broacha

Okay, thank you.

Operator

We have our next question from the line of Anubhav from Prescient Capital. Please go ahead.

Anubhav Mukherjee
Co-Founder, Prescient Capital

Am I audible?

Operator

Yes, sir, you are.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes, please.

Anubhav Mukherjee
Co-Founder, Prescient Capital

I just have one question, sir. Have you seen any pressure or fall in product realization from last quarter to this quarter?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Have you seen what? A pressure?

Anubhav Mukherjee
Co-Founder, Prescient Capital

Any pressure or fall in, like, your average realization from last quarter to this quarter, like sequentially?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

No. No such things. We have increased the volume.

Anubhav Mukherjee
Co-Founder, Prescient Capital

No, sir, I'm not talking about volume, sir.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

I'm saying I'm talking about the last quarter, the same quarter. I'm not talking about the last calendar quarter. I mean compared to April, June last year and April, June this year.

Anubhav Mukherjee
Co-Founder, Prescient Capital

Yes, sir. My question was like from Q4 FY 2022 to this quarter, like sequentially, have you seen any fall in product realizations or realization has held up like.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Mr. Anubhav, we are not comparing with Q4 last year with this quarter, you know. Ours is a seasonal business and every quarter has a specific role to play. Our Q4 or every financial year is the best quarter. You cannot compare Q4 of last year with Q1 of this year.

Anubhav Mukherjee
Co-Founder, Prescient Capital

Sir, I'm not talking about comparing.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

There is Q1 of last year and Q1 of this year.

Anubhav Mukherjee
Co-Founder, Prescient Capital

Sir, I get that, and I'm not talking about product volume, sir. I'm talking about the pricing, product pricing realization. Like, is there any pressure on the final realization that you're getting?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

No, there's no such thing.

Anubhav Mukherjee
Co-Founder, Prescient Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

The prices are more or less at the same level.

Anubhav Mukherjee
Co-Founder, Prescient Capital

Okay. That's all from my side. Thanks.

Operator

Thank you. We have our next question from the line of Harsh Beria, Professional Investor. Please go ahead.

Harsh Beria
Professional Investor, Private Investor

Hi. Thanks for the opportunity again. You had previously shared volume numbers across markets. Was this overall volume that Sharda shipped, or was this agrochemical volume?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

I think the question was for agrochemical, and what we have shared was for agrochemical.

Harsh Beria
Professional Investor, Private Investor

Okay. My final question is about the price increase of 38% on the entire sales for this quarter. Was this mostly attributed to increasing raw material prices of your non-agrochemical division?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

You're talking about, I mean, the question is related to non-agrochemicals.

Harsh Beria
Professional Investor, Private Investor

Yes.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Am I right?

Harsh Beria
Professional Investor, Private Investor

You had. Yes.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yeah. There has been increase in the prices with efforts that we are putting in. We had not realized the impact of freight. Now we are taking the freight into very serious consideration, and we are putting pressures on our customers to give us a better price, and they are yielding.

Harsh Beria
Professional Investor, Private Investor

Okay. Perfect. Thanks for the clarification. That's it from my side.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Thank you.

Operator

Thank you. We have our next question from the line of Harsh Shah from L&T Mutual Fund. Please go ahead.

Harsh Shah
Research Analyst of Equities, L&T Mutual Fund

Yeah. Thank you. Mr. Bubna, hi. Hope everything is all good at your end.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes, sir.

Harsh Shah
Research Analyst of Equities, L&T Mutual Fund

Yes, sir. Just two questions, sir. You have answered all of the questions very, very thoroughly. Just two questions from my end. First is, apart from Forex management, is there any other way where we can increase our gross margin, or is it purely, you know, we have to try to manage our Forex only?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Forex is one thing. Second is being in constant touch with our customers. If they can somehow realize our situation and give us a better prices. They also have limited freedom on that account because they are also facing competition with their customers.

Harsh Shah
Research Analyst of Equities, L&T Mutual Fund

Yes.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Forex is the main thing.

Harsh Shah
Research Analyst of Equities, L&T Mutual Fund

Understood. Assuming, let's say from now to next quarter, there is no major movement in Forex, our gross margin should remain similar to what we have reported in Q1, or how should we look at it?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

No, sir. It should be better because we are thinking of other means, as I just mentioned in the beginning of this conference call. We are trying to source our products from India. Chinese are also resisting. You know, China also knows that, euro, I mean, what's the fate of euro. They may be having some ways of hedging their losses. They are in some of the cases when we have tried, they'll agree to give us a price in euros, and we will increase that share of buying in euros.

Harsh Shah
Research Analyst of Equities, L&T Mutual Fund

Okay. Understood, sir. Sir, with so many issues that we are currently hearing in overall macroeconomy of Europe, earlier you had already mentioned that licensing has already got very complex and is taking a bit more time. If it is taking a bit more money, has that timeline and that expenditure further increased now, or has it remained similar to what it was last quarter or say last year?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

It is constantly increasing.

Harsh Shah
Research Analyst of Equities, L&T Mutual Fund

Okay.

Operator

Harsh Shah.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Since all those expenses are in euros, if you compare it with dollar, then it may not be increasing. In terms of euros, it is increasing.

Harsh Shah
Research Analyst of Equities, L&T Mutual Fund

Okay, sir. Understood, sir. That's it, sir. Those are the two questions from my side, sir. Thank you and all the very best.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Thank you. Thank you.

Operator

We have our next question from the line of Gagan Thareja from ASK Investment Managers. Please go ahead.

Gagan Thareja
Portfolio Manager, ASK Investment Manager

Yeah, good evening. Am I audible?

Operator

Sir, your volume is a little low.

Gagan Thareja
Portfolio Manager, ASK Investment Manager

Yeah. Is it better now? Can you hear me?

Operator

Yes, sir.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Now it is better.

Gagan Thareja
Portfolio Manager, ASK Investment Manager

Yeah. My first question is around your depreciation. The depreciation amount is down from Q4 to Q1, and the depreciation varies across quarters in any given year. Could you explain the reason for that?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Because we are constantly getting registrations throughout the year. As we receive the registration, all the investment made on that registration which was earlier bracketed under a capital work in progress is getting capitalized.

Gagan Thareja
Portfolio Manager, ASK Investment Manager

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

That is why there's a variation from quarter to quarter, and it's a continuous process for us.

Gagan Thareja
Portfolio Manager, ASK Investment Manager

Right. I understand that, but from Q4 of last year to Q1 of this year, why should the depreciation fall?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, again, as I explained you, we get many registrations in the last quarter or end of the third quarter, and they get capitalized in the fourth quarter.

Gagan Thareja
Portfolio Manager, ASK Investment Manager

Okay. Right. Second question, sir. In Europe, what is your exposure to Eastern Europe in sales?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

It is much lesser compared to Western Europe.

Gagan Thareja
Portfolio Manager, ASK Investment Manager

Any number you could give us? Small part number, approximate.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

We have not segregated this because the agriculture in the Eastern Europe is much lesser. The population in Eastern Europe is much lesser. The demand in Eastern Europe is much lesser.

Gagan Thareja
Portfolio Manager, ASK Investment Manager

Okay. Okay, sir. Thank you. I'll get back in the queue.

Operator

Thank you. We have our next question from the line of Ankush Agrawal from Surge Capital. Please go ahead.

Ankush Agrawal
Founder, Surge Capital

Yeah. Hi, sir. Thank you for the follow-up. Again, on the business front, what I wanted to understand is that, say if we launch a new product, how does that product performs over the years? Does it start at, say, you know, a small amount in year one and then gradually scales up over next three, four, five years? Or we start big and then it's, you know, kind of, stays the same over medium term.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, I have not understood your question. The words are getting mixed up. Please repeat it. Just little slowly.

Ankush Agrawal
Founder, Surge Capital

Yes. I'll be slow. Yeah. What I am trying to understand is that, say Sharda launches a product, right? How does it perform over the years? Like, in year one, do we start small and then over the years, next three, four, five years, really scales up? Or we start with a decent share and then over the years stay kind of similar or, some small growth for individual products.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

We start at a, say, this moderate level.

Ankush Agrawal
Founder, Surge Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Gradually we increase it because the customers have to get used to our product.

Ankush Agrawal
Founder, Surge Capital

Right.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

They must get convinced that our product will perform, and they have a test on the quality. Even a customer, if he needs 100 L of product, he'll start with maybe 10 L, 15 L or 20 L from us, you know.

Ankush Agrawal
Founder, Surge Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Only if he is convinced, then he'll increase it to 40 L, 50 L.

Ankush Agrawal
Founder, Surge Capital

Right. The old products for us are growing, right?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes.

Ankush Agrawal
Founder, Surge Capital

Okay.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

At the same time products, if they become commodity, then they start going down in the proportion.

Ankush Agrawal
Founder, Surge Capital

Okay. When does that happen? If a product goes generic in, say, this year, so over next three, four, five years, how long does it take for the product to, you know, become such that it will start falling like the overall market?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, again, I'll have to request you to please. Your questions are not very well comprehensible. Can you repeat the question once again, little slowly?

Ankush Agrawal
Founder, Surge Capital

I'll take that off and I think that will need some explanation. Lastly, just a clarification. When we sell our pro-

Operator

Sir, I request you to come back in the queue, please.

Ankush Agrawal
Founder, Surge Capital

Okay, fine.

Operator

Sorry.

Ankush Agrawal
Founder, Surge Capital

Thank you.

Operator

Thank you. We have our next question from the line of Sameer Deshpande from Fairdeal Investments. Please go ahead.

Sameer Deshpande
Owner, Fairdeal Investments

Good evening, sir. We have been performing very well throughout the last year or almost two year. After COVID also, we have done very well. This quarter seems to be an aberration, and mainly due to the things beyond control. No one really could predict that type of currency movements. It is understandable that this will be an aberration, I hope. From Q2 onward, as you mentioned, if the euro-dollar parity continues at the same level 29, 30 levels, which we used to attain.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, this last sentence is not very clear. Understood, most of the question. Last sentence you have to repeat.

Sameer Deshpande
Owner, Fairdeal Investments

Yeah. I will repeat it. I think you mentioned if the euro-to-dollar parity currently, which was there in

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes.

Sameer Deshpande
Owner, Fairdeal Investments

If it remains the same, do we hope to return to the gross margin levels of 29%-30%, which we were achieving over the last year?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

This is a very hypothetical. If the euro-dollar exchange rate improves, then our profitability and gross margins will improve. That's the only thing I can say in general. To what extent and other things, it is a pure guess, which is very easy to guess, you know, for anybody.

Sameer Deshpande
Owner, Fairdeal Investments

Okay. Now, the second question is regarding, you mentioned about a guidance which was around 15%-20% for the year, and the operating margins as the EBITDA of around 18%-20%. Is it correct if I heard?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Yes, please.

Sameer Deshpande
Owner, Fairdeal Investments

Okay. The other income for this year has gone up from INR 6 crore to around INR 20 crore.

Operator

Deshpande, I request you to come back in the queue, please.

Sameer Deshpande
Owner, Fairdeal Investments

Okay, thank you.

Operator

Thank you. We have our next question from the line of Ramesh Sankaranarayanan from Nirmal Bang Equities. Please go ahead.

Ramesh Sankaranarayanan
Research Analyst, Nirmal Bang Equities

Good evening, Bubna . Thank you very much.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Good evening, sir.

Ramesh Sankaranarayanan
Research Analyst, Nirmal Bang Equities

Yeah. My first thought is, in terms of your strategy on new products, can you share how many products you are launching this year? How many you plan to launch next year? And how do you see your ability to possibly, you know, going for higher margin products as you launch new products?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

See, every new product that we launch commands a higher margin compared to the products which are already being marketed, mainly because of the competition factor in. This process will continue.

Ramesh Sankaranarayanan
Research Analyst, Nirmal Bang Equities

Okay. The second thing is, okay, looking at the European market, the regulators are trying to discourage the use of chemical pesticides and, you know, pushing the industry to move for sustainable and biological products. What is the challenge you are facing? How do you plan to overcome this given that you have a large exposure to Europe?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Sir, this is not a very serious challenge for us. I feel that the current trend will continue. There could be a marginal desire to go for, of course, bioproducts. The availability and it's in practice that alternative is not very challenging.

Ramesh Sankaranarayanan
Research Analyst, Nirmal Bang Equities

Sir, one final thought. In terms of the trend in the container freight and the availability of chemicals from China, how is the situation now? Do you see the container freight rate coming down, and do you see the supply from China easing in terms of the volume of material available?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

There is an improvement. The freight rates are softening and availability of the shipping space is also improving. It is not as bad as it was about two, three months back.

Ramesh Sankaranarayanan
Research Analyst, Nirmal Bang Equities

How about availability of chemical raw materials?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

That is also improving.

Ramesh Sankaranarayanan
Research Analyst, Nirmal Bang Equities

Thank you very much, sir. Wish you all the best.

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Thank you.

Operator

Thank you. We have our next question from the line of Anurag Dinkar Patil from Roha Asset Managers. Please go ahead.

Anurag Dinkar Patil
Equity Research Analyst, Roha Asset Managers

Yeah. Other income has increased significantly to INR 20 crore in Q1. Can you explain what is the reason behind it?

Operator

One minute.

Ashok Vashisht
CFO, Sharda Cropchem

Hello.

Anurag Dinkar Patil
Equity Research Analyst, Roha Asset Managers

Hello.

Ashok Vashisht
CFO, Sharda Cropchem

Yeah, this is Ashok Vashisht. On other income, this is a purely, you know, accounting, you know, presentation. There are two components. Profit on sale of mutual fund, INR 11.4 crore has come in other income. There is a loss on some of the investment which we sold mutual fund. There is a loss of, you know, INR 12.15 crore, which is forming part of other expenses. This is a purely, you know, as per the accounting presentation. You have to net it off to see the net impact.

Anurag Dinkar Patil
Equity Research Analyst, Roha Asset Managers

Okay. Sir, you have maintained the guidance of around 18%-20% EBITDA margins for the year and current quarter, they are significantly lower. Can we say the second half-

Ashok Vashisht
CFO, Sharda Cropchem

I think.

Anurag Dinkar Patil
Equity Research Analyst, Roha Asset Managers

Yeah. In the second half, are you expecting significant improvement in the margins?

Ashok Vashisht
CFO, Sharda Cropchem

Yeah, we are expecting increase, yes. The guidance is for the, you know, on yearly basis, which we are maintaining, 18%-20%.

Anurag Dinkar Patil
Equity Research Analyst, Roha Asset Managers

Okay. That's it from my side. Thank you very much.

Operator

Thank you. We'll take our last question from the line of Himanshu Binani from Prabhudas Lilladher. Please go ahead.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Yes, thank you. Thank you for taking my question, sir. Again, the question is on the gross margin side of the business. I was actually trying to understand one thing. You have taken a hit into the gross margin, and that was largely towards the Forex side. While you have taken a Forex loss of somewhere around INR 43 crore. I was just trying to understand the impact basically. Despite taking a 38% increase in the price, we had a 400 basis point decline into the gross margin. Can you please quantify what has been the overall impact basically into the gross margin, which was led by the Forex?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

I will, I'll ask Mr. Ashok Vashisht to answer that question.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Sure, sir.

Ashok Vashisht
CFO, Sharda Cropchem

There are two things basically. One is realized and the other one is unrealized. The INR 43 crore which you are seeing is basically that is a notional loss and not actual loss. The quarter end positions of accounts payable. In terms of which basically is impacting us in the gross margin is wherein you know I have already you know made the payment for that in U.S. dollars and you know our liability is in euros. So the impact could be to the tune of 4%-4.5%, basically, which is already you know forming part of the P&L.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Okay. Okay, sir.

Ashok Vashisht
CFO, Sharda Cropchem

Yeah.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

And so-

Yeah.

One more thing basically on the other expenditure. After excluding that INR 12 crore-

Ashok Vashisht
CFO, Sharda Cropchem

Yeah.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Number also, our other expenses on an absolute number is coming way higher. Last year it was somewhere around INR 65 crore-INR 66 crore.

Ashok Vashisht
CFO, Sharda Cropchem

Yeah, it is higher for three specific reasons. One is freight, because we did, you know, the revenue growth is 32%. Secondly, you know, there is a increase in the legal and professional fee. Basically, you know, we are increasing, you know, building base for our professionals across the globe to, you know, ensure the growth, you know, going forward. There are the two key reasons, freight and increase in the legal and professional fee.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Sir, any numbers to quantify on that side?

Ashok Vashisht
CFO, Sharda Cropchem

The freight, you know, which was increased by 31% and which was INR 12.6 crores last year, same quarter. Now it is INR 16.5 crores.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

This year it is INR 6.5 crore.

Ashok Vashisht
CFO, Sharda Cropchem

INR 16.5 crores.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

INR 16.5 crores. Okay.

Ashok Vashisht
CFO, Sharda Cropchem

Yeah.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Sir, on the legal and professional fee?

Ashok Vashisht
CFO, Sharda Cropchem

Legal and professional, which you can see in the annual report also. I mean, the results also, it's INR 32 crore versus now INR 49 crores now.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Okay. Okay, sir.

Ashok Vashisht
CFO, Sharda Cropchem

Yeah.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Sir, one last question basically on the registration breakup, if you can provide us with the numbers region-wide.

Ashok Vashisht
CFO, Sharda Cropchem

Yeah, sure. Total is INR 2,719 as of 30 June.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Right.

Ashok Vashisht
CFO, Sharda Cropchem

Out of that, 1,445 Europe.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Right.

Ashok Vashisht
CFO, Sharda Cropchem

INR 280 NAFTA. INR 753, Latin America, and INR 241, rest of the world.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

INR 241. Sir, on the pipeline numbers also.

Ashok Vashisht
CFO, Sharda Cropchem

On the pipeline 761 Europe.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Right.

Ashok Vashisht
CFO, Sharda Cropchem

135 NAFTA.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Mm-hmm.

Ashok Vashisht
CFO, Sharda Cropchem

INR 162 Latin America and rest of the world INR 95. INR 115 the total.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

INR 115. Okay. Sure, sir. Thank you.

Ashok Vashisht
CFO, Sharda Cropchem

Yeah. Yeah.

Himanshu Binani
Equity Research Analyst, Prabhudas Lilladher

Thank you, sir.

Operator

Thank you, Mr. Binani. As there are no further questions, I would now like to hand the conference over to Mr. Manish Mahawar from Antique Stock Broking Limited. Over to you, sir.

Manish Mahawar
SVP of Institutional Equities, Antique Stock Broking Ltd

Yeah, thank you, Yashvi. On behalf of Antique Stock Broking, I would like to thank the team of Sharda Cropchem for providing us an opportunity to host the call. Bubna, would you like to make closing comments?

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

No, Manish, I think we have spoken enough.

Manish Mahawar
SVP of Institutional Equities, Antique Stock Broking Ltd

Thanks, sir. Yeah, Yashvi, we can close the call, please.

Operator

Sure. On behalf of

R.V. Bubna
Chairman and Managing Director, Sharda Cropchem

Thank you.

Operator

Antique Stock Broking Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.

Powered by